BALPHARMA105.50

Bal Pharma Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹168 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations339.2303.1311.7334.4
Other Income2.82.21.91.6
Total Income342.1305.3313.6336.1
Expenses
+ Cost of Materials Consumed181.6149.9161.0173.4
+ Purchases of Stock-in-Trade11.215.19.28.1
+ Changes in Inventories-1.1-7.0-12.2-6.0
+ Employee Benefit Expense60.462.466.568.7
+ Finance Costs15.316.916.817.2
+ Depreciation & Amortisation10.19.811.111.3
+ Other Expenses55.653.255.356.3
Total Expenses333.0300.1307.7329.2
EBITDA31.529.631.933.8
EBIT21.519.820.822.4
Profit
PBT before Exceptional Items9.05.15.96.9
Pretax Income9.05.15.96.9
+ Current Tax3.20.00.00.0
+ Deferred Tax-1.6-2.1-0.4-0.4
Tax Expense1.6-2.1-0.4-0.4
+ Share of Associates & JVs0.0-0.00.00.0
Net Income7.47.26.37.2
+ Net Income — Continuing Ops7.47.26.37.2
+ Other Comprehensive Income0.40.00.40.4
Total Comprehensive Income7.87.26.87.7
Net Income to Common7.47.26.37.2
Minority Interest0.10.00.00.0
Per Share
Basic EPS4.944.563.954.54
Diluted EPS4.964.563.954.54
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs1.20.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income0.4
+ Tax on Items NOT to be Reclassified-0.4
Comprehensive Income — Owners of Parent0.0-0.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations4.944.563.954.54
Diluted EPS — Continuing Operations4.964.563.954.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit147.5145.2153.7158.8
Gross Margin %43.4747.9049.3247.50
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)9.05.15.96.9
Net Income Adj (tax-effected)7.47.26.37.2
EPS Adj4.944.563.954.54
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital15.815.915.915.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.